We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+5.04%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$6.97B
AUM Growth
-$106M
Cap. Flow
-$271M
Cap. Flow %
-3.88%
Top 10 Hldgs %
34.81%
Holding
187
New
15
Increased
42
Reduced
87
Closed
11

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$28.5M
2
CLDX icon
Celldex Therapeutics
CLDX
+$26.8M
3
EXAS
Exact Sciences
EXAS
+$15.3M
4
TNDM icon
Tandem Diabetes Care
TNDM
+$13.7M
5
CRL icon
Charles River Laboratories
CRL
+$6.89M

Top Sells

Rank Stock Value
1
RDUS
Radius Health, Inc.
RDUS
+$91.2M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$38.7M
3
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$24M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$19.3M
5
AXSM icon
Axsome Therapeutics
AXSM
+$16M

Sector Composition

Rank Sector Weight
1 Healthcare 99.34%
2 Industrials 0.59%
3 Energy 0.02%
4 Communication Services 0.01%
5 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IONS icon
1
Ionis Pharmaceuticals
IONS
$8.99B
$419M 6.01%
9,463,400
-313,128
-3% -$13.2M
VRTX icon
2
Vertex Pharmaceuticals
VRTX
$123B
$335M 4.81%
1,158,126
-18,010
-2% -$5.18M
ARGX icon
3
argenx
ARGX
$53.8B
$332M 4.76%
919,346
-14,457
-2% -$5.36M
NBIX icon
4
Neurocrine Biosciences
NBIX
$17.2B
$303M 4.35%
2,855,146
+10,841
+0.4% +$1.1M
ALNY icon
5
Alnylam Pharmaceuticals
ALNY
$35.7B
$192M 2.75%
956,762
-101,424
-10% -$19.3M
MRNA icon
6
Moderna
MRNA
$24.5B
$184M 2.65%
1,559,801
-17,550
-1% -$2.66M
INCY icon
7
Incyte
INCY
$23.4B
$183M 2.62%
2,744,277
-29,100
-1% -$2.15M
ISRG icon
8
Intuitive Surgical
ISRG
$122B
$168M 2.42%
898,092
-11,256
-1% -$2.42M
ITCI
9
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$155M 2.22%
3,329,279
-20,100
-0.6% -$1.05M
AXNX
10
DELISTED
Axonics, Inc. Common Stock
AXNX
$154M 2.22%
2,193,200
-120,652
-5% -$8.32M
ABT icon
11
Abbott
ABT
$175B
$152M 2.18%
1,569,851
-3,956
-0.3% -$422K
UNH icon
12
UnitedHealth
UNH
$387B
$150M 2.15%
296,754
-5,290
-2% -$2.78M
BSX icon
13
Boston Scientific
BSX
$65.4B
$147M 2.11%
3,804,047
-46,124
-1% -$1.85M
SAGE
14
DELISTED
Sage Therapeutics
SAGE
$116M 1.67%
2,970,678
-2,500
-0.1% -$96.6K
AGIO icon
15
Agios Pharmaceuticals
AGIO
$2.36B
$115M 1.65%
4,058,792
-4,000
-0.1% -$107K
JAZZ icon
16
Jazz Pharmaceuticals
JAZZ
$15.5B
$110M 1.58%
823,839
-94,068
-10% -$14.3M
MYOV
17
DELISTED
Myovant Sciences Ltd.
MYOV
$106M 1.52%
5,912,639
-7,000
-0.1% -$112K
ARVN icon
18
Arvinas
ARVN
$517M
$97.5M 1.4%
2,190,762
+66,486
+3% +$3.23M
SYK icon
19
Stryker
SYK
$123B
$96.6M 1.39%
476,932
-702
-0.1% -$148K
DHR icon
20
Danaher
DHR
$144B
$94.9M 1.36%
414,467
+3,834
+0.9% +$939K
RLAY icon
21
Relay Therapeutics
RLAY
$4.34B
$94.1M 1.35%
4,204,820
+172,558
+4% +$3.79M
RVMD icon
22
Revolution Medicines
RVMD
$39.6B
$92.3M 1.32%
4,680,162
+1,296,900
+38% +$28.5M
ELV icon
23
Elevance Health
ELV
$80.9B
$92M 1.32%
202,492
-6,008
-3% -$2.87M
PODD icon
24
Insulet
PODD
$11.4B
$85.8M 1.23%
373,953
-12,382
-3% -$3.1M
EW icon
25
Edwards Lifesciences
EW
$49.4B
$84.8M 1.22%
1,025,715
+15,088
+1% +$1.45M
1
2 3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q3 2022 Portfolio in Review

As of Q3 2022, Bellevue Group held 187 positions worth $6.97B, down 1.5% from $7.07B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Bellevue Group withdrew a net $271M in Q3 2022, closing 11 positions and reducing 87 holdings. Its most notable exit was Radius Health, Inc., an estimated $91.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Industrials and Energy.

Against the trend, Bellevue Group opened a new position in Zai Lab worth $1.28M.

  • Bellevue Group's largest Q3 2022 buy was Zai Lab: 36,600 shares worth $1.28M.
  • Bellevue Group added most to Revolution Medicines in Q3 2022, an estimated $28.5M increase.
  • Bellevue Group's biggest Q3 2022 reduction was Sarepta Therapeutics, cutting an estimated $38.7M.
  • Bellevue Group fully exited Radius Health, Inc. in Q3 2022, selling an estimated $91.2M.
  • Bellevue Group's ten largest holdings make up 35% of its $6.97B portfolio in Q3 2022.
  • Bellevue Group opened 15 new positions and closed 11 in Q3 2022.
  • Bellevue Group's portfolio value fell 1.5% quarter-over-quarter to $6.97B.

Based on Bellevue Group's 13F filing for Q3 2022, filed 14 Nov 2022.